Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molidustat in ESA-untreated dialysis patients with renal anemia
NCT03351166Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of molidustat in anemia of chronic kidney disease, sponsored by Bayer. Primary endpoints: Rate of rise in Hemoglobin level at 8 weeks and Responder rate at 24 weeks. Started Jan 2018; status: completed.
02
Drugs
molidustat
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT03351166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351166.